section name header

Indications

High Alert


Contraind./Precautions

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects

CV: hypotension, QT interval prolongation (especially with cumulative doses >27 mg/day), tachycardia

Derm: pruritus, sweating, flushing, rash

Endo: ADRENAL INSUFFICIENCY

F and E: hypocalcemia, hypokalemia, hypomagnesemia, hypophosphatemia

GI: nausea, vomiting, amylase, diarrhea, dry mouth, dyspepsia, flatulence

Hemat: anemia

Local: extravasation

MS: back pain, muscle spasms

Neuro: constipation, dizziness, headache, sedation, anxiety, insomnia, restlessness

Resp: hypoxia, cough, dyspnea, RESPIRATORY DEPRESSION(INCLUDING CENTRAL SLEEP APNEA AND SLEEP-RELATED HYPOXEMIA)

Misc: allodynia, fever, opioid-induced hyperalgesia, physical dependence, psychological dependence, tolerance

Interactions

Drug-drug:

Availability

Route/Dosage

US Brand Names

Olinvyk

Action

  • Binds to mu-opioid receptors in the CNS. Alters the perception of and response to painful stimuli while producing generalized CNS depression.
Therapeutic effects:
  • Decrease in severity of pain.

Classifications

Therapeutic Classification: opioid analgesics

Pharmacologic Classification: opioid agonists

Pharmacokinetics

Absorption: IV administration results in complete bioavailability.

Distribution: Extensively distributed to extravascular tissues.

Metabolism/Excretion: Primarily metabolized by the liver via the CYP3A4 and CYP2D6 isoenzymes into inactive metabolites. The CYP2D6 isoenzyme exhibits genetic polymorphism; 7% of population may be poor metabolizers and may have significantly oliceridine concentrations and an risk of adverse effects. Primarily excreted in urine (70%) as metabolites (<10% excreted in urine as unchanged drug).

Half-Life: 1.3–3 hr.

Contr. Subst. Schedule

Schedule II (C-II)

Time/Action Profile

(analgesia)

ROUTEONSETPEAKDURATION
IV2–5 min10–15 min1–2 hr



Patient/Family Teaching

Pronunciation

OH-li-SER-i-deen